The annual meeting of the American Society of Nephrology (Kidney Week) was held this year from Oct. 23 to 27 in San Diego, ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research ...

The biotech industry in Boston is more than just a source of jobs or a pillar of the local economy; it is a powerful force in the global fight for better health. Known for its prestigious universities ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

SAVANNAH, Ga. — When Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, pediatric neurologist Nancy L. Kuntz, MD, ...

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...

Biogen is tapping some top pharma talent to lead its medical efforts. Daniel Quirk, M.D., is the biotech’s new chief medical officer and head of medical affairs. Quirk formerly served as a senior vice ...

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...